Latest News and Press Releases
Want to stay updated on the latest news?
-
BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
-
NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”) announces the launch of a public offering of common shares in...
-
BROOKFIELD, Conn., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Photronics, Inc. (Nasdaq:PLAB), a worldwide leader in photomask technologies and solutions, today announced that it will participate in the 28th...
-
Í viðhengi er tilkynning um viðskipti stjórnenda og tengdra aðila sem lögð var inn til birtingar hjá fjármálaeftirliti Lúxemborgar, Luxembourg Commission de Surveillance du Secteur Financier (CSSF),...
-
Attached is a copy of a filing with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding transactions of managers and closely associated persons, announcing the acquisition...
-
Í viðhengi eru tvær tilkynningar um viðskipti stjórnenda og tengdra aðila sem lögð var inn til birtingar hjá fjármálaeftirliti Lúxemborgar, Luxembourg Commission de Surveillance du Secteur Financier...
-
Attached is a copy of two filings with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding transactions of managers and closely associated persons, announcing the...
-
VANCOUVER, Columbia Británica, Jan. 06, 2026 (GLOBE NEWSWIRE) -- ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) ("ZenaTech"), una empresa de soluciones tecnológicas empresariales...
-
Positive results from Phase 3 HERIZON-GEA-01 results support Ziihera as the HER2-targeted agent-of-choice in HER2+ first-line metastatic GEA and Ziihera plus chemotherapy to replace trastuzumab as the...
-
NXP announced its new eIQ Agentic AI Framework, a trusted foundation to rapidly prototype and deploy optimized, secure, autonomous AI systems at the edge.